IsoRay, Inc. (NYSEAMERICAN:ISR) was the target of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 771,025 shares, a decrease of 6.8% from the April 15th total of 827,421 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily volume of 178,512 shares, the days-to-cover ratio is currently 4.3 days.
Shares of NYSEAMERICAN:ISR opened at $0.44 on Wednesday. IsoRay has a fifty-two week low of $0.27 and a fifty-two week high of $1.22.
IsoRay (NYSEAMERICAN:ISR) last issued its earnings results on Thursday, May 9th. The healthcare company reported ($0.02) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.02). The company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.92 million.
Large investors have recently modified their holdings of the stock. Highland Private Wealth Management bought a new position in shares of IsoRay during the fourth quarter worth $39,000. Vanguard Group Inc boosted its position in shares of IsoRay by 24.7% during the third quarter. Vanguard Group Inc now owns 1,857,268 shares of the healthcare company’s stock worth $964,000 after acquiring an additional 367,324 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of IsoRay by 24.7% during the third quarter. Vanguard Group Inc. now owns 1,857,268 shares of the healthcare company’s stock worth $964,000 after acquiring an additional 367,324 shares during the last quarter.
IsoRay Company Profile
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Featured Story: Why do company’s buyback their stock?
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.